Incidence of Malignancy after Living Kidney Transplantation: A Multicenter Study from Iran
dc.contributor.author | Einollahi, B | |
dc.contributor.author | Rostami, Z | |
dc.contributor.author | Nourbala, MH | |
dc.contributor.author | Lessan-Pezeshki, M | |
dc.contributor.author | Sim-Foroosh, N | |
dc.contributor.author | Nemati, E | |
dc.contributor.author | Pourfarziani, V | |
dc.contributor.author | Beiraghdar, F | |
dc.contributor.author | Nafar, M | |
dc.contributor.author | Pour-Reza-Gholi, F | |
dc.contributor.author | Mazdeh, MM | |
dc.contributor.author | Amini, M | |
dc.contributor.author | Ahmadpour, P | |
dc.contributor.author | Makhdoomi, K | |
dc.contributor.author | Ghafari, A | |
dc.contributor.author | Ardalan, MR | |
dc.contributor.author | Khosroshahi, HT | |
dc.contributor.author | Oliaei, F | |
dc.contributor.author | Shahidi, S | |
dc.contributor.author | Abbaszadeh, S | |
dc.contributor.author | Fatahi, MR | |
dc.contributor.author | Hiedari, F | |
dc.contributor.author | Makhlogh, A | |
dc.contributor.author | Azmandian, J | |
dc.contributor.author | Samimagham, HR | |
dc.contributor.author | Shahbazian, H | |
dc.contributor.author | Nazemian, F | |
dc.contributor.author | Naghibi, M | |
dc.contributor.author | Khosravi, M | |
dc.contributor.author | Monfared, A | |
dc.contributor.author | Mosavi, SM | |
dc.contributor.author | Ahmadi, J | |
dc.contributor.author | Jalalzadeh, M | |
dc.date.accessioned | 2018-08-26T08:05:50Z | |
dc.date.available | 2018-08-26T08:05:50Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/49901 | |
dc.description.abstract | Malignancy is a common complication after renal transplantation. However, limited data are available on post-transplant malignancy in living kidney transplantation. Therefore, we made a plan to evaluate the incidence and types of malignancies, association with the main risk factors and patient survival in a large population of living kidney transplantation. We conducted a large retrospective multicenter study on 12525 renal recipients, accounting for up to 59% of all kidney transplantation in Iran during 22 years follow up period. All information was collected from observation of individual notes or computerized records for transplant patients. Two hundred and sixty-six biopsy-proven malignancies were collected from 16 Transplant Centers in Iran; 26 different type of malignancy categorized in 5 groups were detected. The mean age of patients was 46.2 +/- 12.9 years, mean age at tumor diagnosis was 50.8 +/- 13.2 years and average time between transplantation and detection of malignancy was 50.0 +/- 48.4 months. Overall tumor incidence in recipients was 2%. Kaposis' sarcoma was the most common type of tumor. The overall mean survival time was 117.1 months (95% CI: 104.9-129.3). In multivariate analysis, the only independent risk factor associated with mortality was type of malignancy. This study revealed the lowest malignancy incidence in living unrelated kidney transplantation. | |
dc.language.iso | English | |
dc.relation.ispartof | JOURNAL OF CANCER | |
dc.subject | malignancy | |
dc.subject | kidney transplantation | |
dc.subject | incidence | |
dc.title | Incidence of Malignancy after Living Kidney Transplantation: A Multicenter Study from Iran | |
dc.type | Article | |
dc.citation.volume | 3 | |
dc.citation.spage | 246 | |
dc.citation.epage | 256 | |
dc.citation.index | Web of science | |
dc.identifier.DOI | https://doi.org/10.7150/jca.3042 |